Nanobiotix SA

Nanobiotix SA engages in research and development of nanoparticle-based technologies for the treatment of cancer. The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. It also engages in the development of magnetic particles and laser activated nanoparticles for the treatment and diagnosis of cancer. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #NBTXR3--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced positive new preclinical data investigating first-in-class radioenhancer NBTXR3, which is being evaluated as a tumor-agnostic, combo-agnostic product candidate across several tumor types. The data is being shared via poster

NANOBIOTIX: Preclinical Data Presented at First AACR Virtual Special Conference on Radiation Science and Medicine Showed NBTXR3 Combo Overcomes Anti-PD-1 Resistance, Promotes Strong Abscopal Effect and Long-Term Anti-Cancer Memory

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #cancer--Regulatory News: NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced its revenues for the fourth quarter and full year ended December 31, 2020. Full Year 2020 Revenue     Twelve Months Ended December 31st K€   2020   2019 Revenues   50   68           Of which licenses   -   - Of which services   50

NANOBIOTIX 2020 Q4 and Annual Revenues

NBTXR3 has shown significant ability to improve effectiveness of radiotherapy in clinical studies. Approximately 60% of all cancer patients receive some for of radiotherapy.

Nanobiotix Will Disrupt Oncological Radiotherapy

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #NBTXR3--Regulatory News: “We believe that NBTXR3 could have a positive impact for patients with cancer in any case where radiotherapy is a part of the standard of care. Expansion into esophageal cancer represents not only another step toward achieving our goals, it also highlights the ongoing progress of our clinical collaboration agreement with The University of Texas MD Anderson Cancer Center.” – Laurent Levy, CEO of Nanobiotix NANOBIOTIX (Euronext: NANO – N

NANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company”), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, today announced positive first results from the complete phase Ib part of a phase Ib/II study evaluating NBTXR3 (PEP503) activated by radiotherapy with concurrent chemotherapy. This study is sponsored and a

Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy and increasing the proportion of patients that respond to immune checkpoint inhibitors, today announced its global development plan for 2021 and beyond. Radiotherapy, also calle

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – Nasdaq: NBTX – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the closing of an additional 1,095,000 American Depositary Shares (“ADSs”) pursuant to the full exercise of the underwriters' option to purchase additional ADSs in connection with the Company's initial public offering on the Nasdaq Global Select Market. Th

Nanobiotix Announces Closing of Underwriters' Option to Purchase Additional ADSs

PARIS--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the initial closing of its previously announced initial public offering on the Nasdaq Global Select Market by way of a capital increase of 7,300,000 new ordinary shares (the “New Shares”), consisting of a public offering of 5,445,000 ordinary shares in the form of Am

NANOBIOTIX Announces Closing of Global Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $113.3 Million

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the pricing of its initial public offering on the Nasdaq Global Select Market by way of a capital increase of 7,300,000 new ordinary shares (the “New Shares”), consisting of a public offering of 5,445,000 ordinary shares in the form of American Depo

NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company''), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the filing of an amended registration on form F-1 in connection with its intention to issue and sell, subject to market and other conditions, 6,500,000 ordinary shares of the Company in an initial public offering of American Depositary Shares (“ADSs

News for Nanobiotix SA Stock (NBTX)